CALIFORNIA HEART CENTER FOUNDATION: Form 990, tax year 2017

View the entire original 990 at ProPublica ↗

Organization
CALIFORNIA HEART CENTER FOUNDATION (EIN 95-4772979)
Tax period
2017-01-01 to 2017-12-31
Filed
2018-11-15
IRS object ID
201813199349320421
Schema version
2017v2.2
Source
Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header ReturnHeader

FieldValueIRS element (for citing)
Return2018-11-15T20:44:58-06:00ReturnTs
Tax Period End2017-12-31TaxPeriodEndDt

Preparer Firm PreparerFirmGrp

FieldValueIRS element (for citing)
Preparer Firm EIN346565596PreparerFirmEIN

Preparer Firm Name PreparerFirmName

FieldValueIRS element (for citing)
Business Name Line1ERNST & YOUNG US LLPBusinessNameLine1Txt

Preparer US Address PreparerUSAddress

FieldValueIRS element (for citing)
Address Line118101 VON KARMAN AVENUE SUITE 1700AddressLine1Txt
CityIRVINECityNm
State AbbreviationCAStateAbbreviationCd
ZIP92612ZIPCd
FieldValueIRS element (for citing)
Return Type990ReturnTypeCd
Tax Period Begin2017-01-01TaxPeriodBeginDt

Filer Filer

FieldValueIRS element (for citing)
EIN954772979EIN

Business Name BusinessName

FieldValueIRS element (for citing)
Business Name Line1CALIFORNIA HEART CENTER FOUNDATIONBusinessNameLine1Txt
FieldValueIRS element (for citing)
Business Name ControlCALIBusinessNameControlTxt
Phone3102488327PhoneNum

US Address USAddress

FieldValueIRS element (for citing)
Address Line18536 WILSHIRE BOULEVARD 3RD FLOORAddressLine1Txt
CityBEVERLY HILLSCityNm
State AbbreviationCAStateAbbreviationCd
ZIP90211ZIPCd

Business Officer BusinessOfficerGrp

FieldValueIRS element (for citing)
PersonJON KOBASHIGAWA MDPersonNm
Person TitlePRESIDENTPersonTitleTxt
Phone3102488327PhoneNum
Signature2018-11-15SignatureDt
Discuss With Paid PreparerYes (1)DiscussWithPaidPreparerInd

Preparer Person PreparerPersonGrp

FieldValueIRS element (for citing)
Preparer PersonKARA ADAMSPreparerPersonNm
PTINP00023315PTIN
Phone9497942300PhoneNum

Filing Security Information FilingSecurityInformation

IP Address IPAddress

FieldValueIRS element (for citing)
I Pv4 Address192.231.86.241IPv4AddressTxt
FieldValueIRS element (for citing)
IP2018-11-15IPDt
IP Tm18:41:40IPTm
IP TimezonePSIPTimezoneCd
Filing License TypePFilingLicenseTypeCd
At Submission Creation Device Id5D66495798EA847DC80F6602DD5A7F057B72F91FAtSubmissionCreationDeviceId
At Submission Filing Device Id441AA63A5AD28D5142E9094244EB82DFC70B9A9DAtSubmissionFilingDeviceId
FieldValueIRS element (for citing)
Tax2017TaxYr
Build TS2019-02-21 02:37:17ZBuildTS

Form 990 IRS990

FieldValueIRS element (for citing)
Principal OfficerJON KOBASHIGAWA MDPrincipalOfficerNm

US Address USAddress

FieldValueIRS element (for citing)
Address Line18536 WILSHIRE BOULEVARD 3RD FLOORAddressLine1Txt
CityBEVERLY HILLSCityNm
State AbbreviationCAStateAbbreviationCd
ZIP90211ZIPCd
FieldValueIRS element (for citing)
Gross Receipts$1,689,699GrossReceiptsAmt
Group Return For Affiliates0GroupReturnForAffiliatesInd
Organization501c3Yes (X)Organization501c3Ind
Website AddressWWW.CALHEART.ORGWebsiteAddressTxt
Type Of Organization CorpYes (X)TypeOfOrganizationCorpInd
Formation2000FormationYr
Legal Domicile StateCALegalDomicileStateCd
Activity Or MissionPROMOTE & DEVELOP EDUCATIONAL & SCIENTIFIC RESEARCH TO ADVANCE THE FIELD OF CARDIOVASCULAR MEDICINE.ActivityOrMissionDesc
Voting Members Governing Body5VotingMembersGoverningBodyCnt
Voting Members Independent3VotingMembersIndependentCnt
Total Employee0TotalEmployeeCnt
Total Volunteers3TotalVolunteersCnt
Total Gross UBI$0TotalGrossUBIAmt
Net Unrelated Bus Txbl Incm$0NetUnrelatedBusTxblIncmAmt
PY Contributions Grants$1,531,356PYContributionsGrantsAmt
CY Contributions Grants$1,466,549CYContributionsGrantsAmt
PY Program Service Revenue$298,766PYProgramServiceRevenueAmt
CY Program Service Revenue$223,150CYProgramServiceRevenueAmt
PY Investment Income$6PYInvestmentIncomeAmt
CY Investment Income$0CYInvestmentIncomeAmt
PY Other Revenue$0PYOtherRevenueAmt
CY Other Revenue$0CYOtherRevenueAmt
PY Total Revenue$1,830,128PYTotalRevenueAmt
CY Total Revenue$1,689,699CYTotalRevenueAmt
PY Grants And Similar Paid$0PYGrantsAndSimilarPaidAmt
CY Grants And Similar Paid$0CYGrantsAndSimilarPaidAmt
PY Benefits Paid To Members$0PYBenefitsPaidToMembersAmt
CY Benefits Paid To Members$0CYBenefitsPaidToMembersAmt
PY Salaries Comp Emp Bnft Paid$1,422,984PYSalariesCompEmpBnftPaidAmt
CY Salaries Comp Emp Bnft Paid$1,388,413CYSalariesCompEmpBnftPaidAmt
PY Total Prof Fndrsng Expns$0PYTotalProfFndrsngExpnsAmt
CY Total Prof Fndrsng Expns$0CYTotalProfFndrsngExpnsAmt
CY Total Fundraising Expense$0CYTotalFundraisingExpenseAmt
PY Other Expenses$408,790PYOtherExpensesAmt
CY Other Expenses$338,546CYOtherExpensesAmt
PY Total Expenses$1,831,774PYTotalExpensesAmt
CY Total Expenses$1,726,959CYTotalExpensesAmt
PY Revenues Less Expenses-$1,646PYRevenuesLessExpensesAmt
CY Revenues Less Expenses-$37,260CYRevenuesLessExpensesAmt
Total Assets BOY$58,893TotalAssetsBOYAmt
Total Assets EOY$24,693TotalAssetsEOYAmt
Total Liabilities BOY$124,806TotalLiabilitiesBOYAmt
Total Liabilities EOY$127,865TotalLiabilitiesEOYAmt
Net Assets Or Fund Balances BOY-$65,913NetAssetsOrFundBalancesBOYAmt
Net Assets Or Fund Balances EOY-$103,172NetAssetsOrFundBalancesEOYAmt
Info In Schedule O Part IIIYes (X)InfoInScheduleOPartIIIInd
MissionTHE MISSION OF THE CALIFORNIA HEART CENTER FOUNDATION IS TO ADVANCE THE FIELD OF CARDIOVASCULAR MEDICINE THROUGH CLINICAL RESEARCH INITIATIVES AND EDUCATIONAL INITIATIVES.MissionDesc
Significant New Program Srvc0SignificantNewProgramSrvcInd
Significant Change0SignificantChangeInd
Expense$1,508,170ExpenseAmt
Revenue$223,150RevenueAmt
DescTHE MISSION OF THE CALIFORNIA HEART CENTER FOUNDATION IS TO ADVANCE THE FIELD OF CARDIOVASCULAR MEDICINE THROUGH CLINICAL RESEARCH INITIATIVES AND EDUCATIONAL INITIATIVES. OUR EFFORTS INCLUDE THE PURSUIT OF COLLABORATIVE RESEARCH PROJECTS WHICH PROMOTE A DEEPER UNDERSTANDING OF DISEASE PROGRESSION AND TEST THE EFFICACY OF NEW STRATEGIES FOR DIAGNOSIS AND TREATMENT. AREAS OF RESEARCH CURRENTLY BEING PURSUED INCLUDE NON-INVASIVE METHODS TO DETECT ORGAN REJECTION, NOVEL IMMUNOSUPPRESSIVE AGENTS, IMMUNE MONITORING STRATEGIES, LONG-TERM COMPLICATIONS SUCH AS CARDIAC ALLOGRAFT VASCULOPATHY, (CONTINUED ON SCHEDULE O)(CONTINUATION FROM FORM 990, PAGE 2)NOVEL METHODS FOR ORGAN PROCUREMENT AND PRESERVATION, NEW MECHANICAL CIRCULATORY SUPPORT DEVICES AND PULMONARY HYPERTENSION. THE ORGANIZATION ALSO SUPPORTS IMPORTANT SCIENTIFIC SYMPOSIA, WHICH ALLOW FOR THE EXCHANGE OF IDEAS AMONG LEADERS IN THE FIELD AND PROVIDE A FORUM FOR EXPERTS TO SHARE THEIR EXPERIENCE AND KNOWLEDGE WITH OTHER PRACTITIONERS. THE ORGANIZATION RESOURCES ARE ALSO LEVERAGED TO SUPPORT A SUMMER RESEARCH INTERNSHIP PROGRAM FOR UNDERGRADUATE STUDENTS WITH AN INTEREST IN MEDICINE AND/OR ACADEMIC RESEARCH. FOLLOWING IS A SUMMARY OF PROJECTS AND PROGRAMS IMPLEMENTED IN 2017: SCIENTIFIC FORUMS AND EDUCATIONAL ACTIVITIES:* "CUTTING EDGE OF TRANSPLANTATION (CEOT)", FEBRUARY 23TH - 25TH, 2017 (PHOENIX, ARIZONA): THIS MEETING, PLANNED BY THE AMERICAN SOCIETY OF TRANSPLANTATION, FEATURED SESSIONS FOCUSED ON HEART AND LUNG TRANSPLANTATION THAT WERE CHAIRED BY DR. JON KOBASHIGAWA AND SPONSORED BY THE CEDARS-SINAI HEART INSTITUTE. FOCUSED ON THE THEME OF "ONE TRANSPLANT FOR LIFE", THE HEART AND LUNG TRACKS EACH FEATURED 3 DEDICATED SESSIONS OVER THREE DAYS ON IMPROVING LONG-TERM OUTCOMES, THUS DECREASING THE LIKELIHOOD OF MULTIPLE TRANSPLANTS OVER A RECIPIENT'S LIFETIME, WITH LECTURES FOCUSING ON THE TREATMENT AND MANAGEMENT OF ANTIBODIES IN SOLID ORGAN TRANSPLANTATION. WITH DR. KOBASHIGAWA'S LEADERSHIP, THE HEART AND LUNG TRACKS FEATURED A FACULTY OF LEADING EXPERTS IN THE FIELD AND ATTRACTED THE HIGHEST ATTENDANCE FROM THE CARDIOTHORACIC COMMUNITY SINCE THE INCEPTION OF THE CEOT MEETING. * "A CONSENSUS CONFERENCE ON FRAILTY IN THORACIC TRANSPLANTATION", APRIL 29TH, 2017 (CHICAGO, IL): THIS CONFERENCE, PLANNED IN COORDINATION WITH THE 2017 AMERICAN TRANSPLANT CONGRESS, WAS DESIGNED TO PROVIDE A FORUM FOR AN IN-DEPTH DISCUSSION AMONG THE LEADING EXPERTS IN THE FIELD, INCLUDING CLINICIANS, SURGEONS AND ALLIED HEALTH. THE CONFERENCE SERVED AS A FIRST STEP IN DEVELOPING NEEDED GUIDELINES FOR THE ASSESSMENT AND TREATMENT OF FRAILTY IN PATIENTS BEING EVALUATED OR LISTED FOR HEART OR LUNG TRANSPLANTATION, TO IMPROVE OUTCOMES AND MINIMIZE POST-TRANSPLANT COMPLICATIONS. SUCH GUIDELINES CAN ALSO BE USED TO DEVELOP A PLATFORM FOR THE DEVELOPMENT OF MULTI-CENTER CLINICAL TRIALS TO FURTHER ASSESS THE EFFICACY OF THERAPIES. ATTENDED BY 47 PARTICIPANTS, REPRESENTING TRANSPLANT CENTERS ACROSS THE UNITED STATES AND CANADA, THE CONFERENCE GENERATED A ROBUST DISCUSSION AND HELPED TO IDENTIFY A PATHWAY TO THE DEVELOPMENT OF GUIDELINES. A PUBLICATION OF CONFERENCE RESULTS IS CURRENTLY PENDING.* "SUCCESS WITH FAILURE: AN ADVANCED HEART DISEASE SYMPOSIUM" (TORRANCE, CA): THIS 1-DAY SYMPOSIUM ON ADVANCED HEART DISEASE TOOK PLACE ON FRIDAY, JUNE 9TH, 2017. TWENTY-TWO FACULTY SPEAKERS COVERED TOPICS RELATED TO THE MANAGEMENT AND TREATMENT OF HEART FAILURE, INTERVENTIONAL PROCEDURES, AND MECHANICAL CIRCULATORY SUPPORT DEVICES AND TRANSPLANTATION AS TREATMENT OPTIONS FOR PATIENTS WITH ADVANCED HEART FAILURE. THE PROGRAM DREW 206 ATTENDEES CONSISTING OF PHYSICIANS, ALLIED HEALTH PROFESSIONALS, INCLUDING NURSE PRACTITIONERS, TRANSPLANT COORDINATORS, PHYSICIAN ASSISTANTS, RNS AND CASE MANAGERS FROM ACROSS SOUTHERN CALIFORNIA. THE PROGRAM WAS EXTREMELY WELL RECEIVED. * "ADVANCED HEART DISEASE VISITING PROFESSORSHIP - JACK COPELAND, MD", SEPTEMBER 11TH - 12TH, 2017: THIS PROFESSORSHIP WAS SPONSORED AND ORGANIZED BY DR. KOBASHIGAWA. THIS YEAR'S VISITING PROFESSOR WAS DR. JACK COPELAND, A PIONEER IN HEART TRANSPLANTATION AND MECHANICAL CIRCULATORY SUPPORT. HIS TWO-DAY VISIT FEATURED A GRAND ROUNDS LECTURE, A FELLOWS' CASE CONFERENCE, A LUNCH LECTURE FOR THE ADVANCED HEART DISEASE CLINICAL TEAMS. DR. COPELAND SHARED HIS UNIQUE PERSPECTIVE ON THE HISTORY AND FUTURE OF TRANSPLANTATION AS 2017 MARKS THE 50TH ANNIVERSARY OF THE FIRST HUMAN HEART TRANSPLANT.* "PRACTICUM IN MECHANICAL CIRCULATORY SUPPORT: AN EXPERT REVIEW" (LOS ANGELES, CA): THIS 2-DAY SYMPOSIUM ON MECHANICAL CIRCULATORY SUPPORT WAS DEVELOPED WITH THE CEDARS-SINAI OFFICE OF CONTINUING MEDICAL EDUCATION AND TOOK PLACE ON OCTOBER 27-28TH, 2017. IN ADDITION TO UTILIZING THE SIMULATION LABS AT CSMC, THE PROGRAM FEATURED 17 EXPERT GUEST FACULTY FROM ACROSS THE UNITED STATES PLUS 12 INTERNAL FACULTY. THE PROGRAM DREW 104 ATTENDEES INCLUDING PHYSICIANS, ALLIED HEALTH PROFESSIONALS, NURSE PRACTITIONERS, AND TRANSPLANT COORDINATORS AND PROVIDED LEARNERS WITH A COMPREHENSIVE OVERVIEW OF MECHANICAL CIRCULATORY SUPPORT.* "UPDATES ON DIAGNOSIS AND TREATMENT OPTIONS FOR CARDIOVASCULAR DISEASE IN THE OUTPATIENT SETTING" - 1-HOUR LUNCH LECTURE EDUCATIONAL SERIES:"THE BASICS OF STRESS TESTING" (MICHELLE KITTLESON, MD, PHD)THIS 1 -HOUR LECTURE WAS HELD ON FEBRUARY 21, 2017 IN THE KAWATA LIBRARY FOR THE CLINICAL STAFF OF CALIFORNIA HEART CENTER. ATTENDED BY 7 PARTICIPANTS, DR. KITTLESON PROVIDED AN OVERVIEW FOR THE INDICATIONS AND CONTRAINDICATIONS FOR STRESS TESTING, AND DISCUSSED THE VARIOUS TYPES AND THE CRITERIA FOR THE APPROPRIATE SELECTION OF STRESS TESTS."CARDIOMEMS" (BABAK AZARBAL, MD)THIS 1 -HOUR LECTURE WAS HELD ON SEPTEMBER 15, 2017 IN THE KAWATA LIBRARY FOR THE CLINICAL STAFF OF CALIFORNIA HEART CENTER. ATTENDED BY 16 PARTICIPANTS, DR. AZARBAL PROVIDED AN OVERVIEW FOR THE USE OF THE CARDIOMEMS DEVICE FOR THE MANAGEMENT OF PATIENTS WITH CONGESTIVE HEART FAILURE. "BASICS OF STRESS TESTING" (MICHELLE KITTLESON, MD, PHD)THIS 1 -HOUR LECTURE WAS HELD ON NOVEMBER 14TH, 2017 IN THE KAWATA LIBRARY FOR THE CLINICAL STAFF OF CALIFORNIA HEART CENTER. ATTENDED BY 12 PARTICIPANTS, DR. KITTLESON PROVIDED AN OVERVIEW FOR THE USE OF THE STRESS TESTING, INCLUDING INDICATIONS, CONTRAINDICATIONS, TYPES OF STRESS TESTS, AND INTERPRETATION.* HEART TRANSPLANT PRECEPTORSHIPS: THROUGHOUT THE YEAR, WE RECEIVE REQUESTS TO PROVIDE EXTENDED OBSERVATIONAL TRAINING OPPORTUNITIES TO PHYSICIANS AND ADVANCE PRACTICE NURSES FROM VARIOUS INSTITUTIONS WITH AN INTEREST IN THE MANAGEMENT OF HEART TRANSPLANT AND MECHANICAL ASSIST DEVICE PATIENTS. IN THE LAST YEAR, WE HOSTED THE FOLLOWING VISITORS:DR. SASHA VUKELIC (MONTEFIORE - ALBERT EINSTEIN SCHOOL OF MEDICINE)DR. BINOY CHATTUPARAMBIL (HEALTHCITY CAYMAN ISLANDS)DR. TAKUMA SATO (NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, JAPAN)* SUMMER RESEARCH INTERNSHIPS: UNDER THE SUPERVISION AND MENTORSHIP OF DR. JON KOBASHIGAWA, SUMMER HEART TRANSPLANT RESEARCH INTERNSHIPS WERE OFFERED TO ELEVEN STUDENTS FOR THE SUMMER OF 2017. THESE INTERNSHIPS PROVIDE STUDENTS AT ALL LEVELS OF TRAINING AN OPPORTUNITY TO LEARN THE CLINICAL RESEARCH PROCESS, INCLUDING MEDICAL LITERATURE REVIEW, STUDY DESIGN, CHART REVIEW/DATA COLLECTION, DATA ANALYSIS, AND ABSTRACT DEVELOPMENT AND SUBMISSION. COMPLETED ABSTRACTS WERE SUBMITTED TO THE AMERICAN FEDERATION OF MEDICAL RESEARCH, A FORUM FOR JUNIOR INVESTIGATORS. THIS YEAR'S GROUP INCLUDES STUDENTS FROM:RICE UNIVERSITY LOYOLA MARYMOUNTUCLAAMHERST COLLEGEUC BERKELEYUSCCSUNCOLUMBIA UNIVERSITYUC DAVISOAKLAND UNIVERSITY BEAUMONT SCHOOL OF MEDICINE* "CURRENT TRENDS IN HEART TRANSPLANTATION: PATIENT EDUCATION SERIES"THIS PATIENT EDUCATION LECTURE BY DR. JON KOBASHIGAWA IS SCHEDULED TWICE A YEAR, COVERING CURRENT TRENDS IN HEART TRANSPLANTATION AND PROVIDING PATIENTS WITH AN OVERVIEW OF CUTTING EDGE INNOVATIONS IN THE FIELD OF HEART TRANSPLANTATION. FORUMS WERE HELD ON THURSDAY, JUNE 22ND, 2017 AND THURSDAY, DECEMBER 7TH, 2017 AT THE MEDICAL CENTER AND ATTENDED BY POST-TRANSPLANT PATIENTS AS WELL AS PATIENTS ON THE WAITING LIST FOR TRANSPLANTATION. CLINICAL RESEARCH:THIS SECTION IS FORMATTED BY TITLE; PRINCIPAL INVESTIGATOR (PI); STATUS; SPONSOR.DCM PRECISION MEDICINE STUDY; EVAN KRANSDORF, MD; ENROLLING; OHIO STATE UNIVERSITYTARGETING INFLAMMATION AND ALLOIMMUNITY IN HEART TRANSPLANT RECIPIENTS WITH TOCILIZUMAB; JIGNESH PATEL, MD, PHD; STUDY INITIATION; MASSACHUSETTS GENERAL HOSPITALTHE MEDICAL ARM OF MECHANICAL CIRCULATORY SUPPORT (MEDAMACS) STUDY; MICHELLE KITTLESON, MD, PHD; ENROLLMENT COMPLETE; UAB/NIHA RANDOMIZED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF THE SHERPA PAK DEVICE FOR COLD STORAGE OF DONOR HEARTS IN TRANSPLANTATION: A PILOT STUDY; FARDAD ESMAILIAN, MD; STUDY START-UP; INTERNAL (PARAGONIX)Desc
Total Program Service Expenses$1,508,170TotalProgramServiceExpensesAmt
Described In Section501c3Yes (1)DescribedInSection501c3Ind
Schedule B RequiredYes (1)ScheduleBRequiredInd
Political Campaign Acty0PoliticalCampaignActyInd
Lobbying Activities0LobbyingActivitiesInd
Subject To Proxy Tax0SubjectToProxyTaxInd
Donor Advised Fund0DonorAdvisedFundInd
Conservation Easements0ConservationEasementsInd
Collections Of Art0CollectionsOfArtInd
Credit Counseling0CreditCounselingInd
Temp Or Permanent Endowments0TempOrPermanentEndowmentsInd
Report Land Building EquipmentYes (1)ReportLandBuildingEquipmentInd
Report Investments Other Sec0ReportInvestmentsOtherSecInd
Report Program Related Invst0ReportProgramRelatedInvstInd
Report Other Assets0ReportOtherAssetsInd
Report Other Liabilities0ReportOtherLiabilitiesInd
Include FIN48 Footnote0IncludeFIN48FootnoteInd
Independent Audit Fincl Stmt0IndependentAuditFinclStmtInd
Consolidated Audit Fincl Stmt0ConsolidatedAuditFinclStmtInd
School Operating0SchoolOperatingInd
Foreign Office0ForeignOfficeInd
Foreign Activities0ForeignActivitiesInd
More Than5000 K To Org0MoreThan5000KToOrgInd
More Than5000 K To Individuals0MoreThan5000KToIndividualsInd
Professional Fundraising0ProfessionalFundraisingInd
Fundraising Activities0FundraisingActivitiesInd
Gaming Activities0GamingActivitiesInd
Operate Hospital0OperateHospitalInd
Grants To Organizations0GrantsToOrganizationsInd
Grants To Individuals0GrantsToIndividualsInd
Schedule J RequiredYes (1)ScheduleJRequiredInd
Tax Exempt Bonds0TaxExemptBondsInd
Engaged In Excess Benefit Trans0EngagedInExcessBenefitTransInd
PY Excess Benefit Trans0PYExcessBenefitTransInd
Loan Outstanding0LoanOutstandingInd
Grant To Related Person0GrantToRelatedPersonInd
Business Rln With Org Mem0BusinessRlnWithOrgMemInd
Business Rln With Fam Mem0BusinessRlnWithFamMemInd
Business Rln With Officer Ent0BusinessRlnWithOfficerEntInd
Deductible Non Cash Contri0DeductibleNonCashContriInd
Deductible Art Contribution0DeductibleArtContributionInd
Terminate Operations0TerminateOperationsInd
Partial Liquidation0PartialLiquidationInd
Disregarded Entity0DisregardedEntityInd
Related EntityYes (1)RelatedEntityInd
Related Organization Ctrl EntYes (1)RelatedOrganizationCtrlEntInd
Transaction With Control Ent0TransactionWithControlEntInd
Trnsfr Exmpt Non Chrtbl Rltd Org0TrnsfrExmptNonChrtblRltdOrgInd
Activities Conducted Prtshp0ActivitiesConductedPrtshpInd
Schedule O RequiredYes (1)ScheduleORequiredInd
IRP Document6IRPDocumentCnt
IRP Document W2 G0IRPDocumentW2GCnt
Backup Wthld ComplianceYes (1)BackupWthldComplianceInd
Employee0EmployeeCnt
Unrelated Bus Incm Over Limit0UnrelatedBusIncmOverLimitInd
Foreign Financial Account0ForeignFinancialAccountInd
Prohibited Tax Shelter Trans0ProhibitedTaxShelterTransInd
Taxable Party Notification0TaxablePartyNotificationInd
Nondeductible Contributions0NondeductibleContributionsInd
Quid Pro Quo Contributions0QuidProQuoContributionsInd
Form8282 Property Disposed Of0Form8282PropertyDisposedOfInd
Rcv Fnds To Pay Prsnl Bnft Cntrct0RcvFndsToPayPrsnlBnftCntrctInd
Pay Premiums Prsnl Bnft Cntrct0PayPremiumsPrsnlBnftCntrctInd
Indoor Tanning Services0IndoorTanningServicesInd
Info In Schedule O Part VIYes (X)InfoInScheduleOPartVIInd
Governing Body Voting Members5GoverningBodyVotingMembersCnt
Independent Voting Member3IndependentVotingMemberCnt
Family Or Business Rln0FamilyOrBusinessRlnInd
Delegation Of Mgmt Duties0DelegationOfMgmtDutiesInd
Change To Org DocumentsYes (1)ChangeToOrgDocumentsInd
Material Diversion Or Misuse0MaterialDiversionOrMisuseInd
Members Or StockholdersYes (1)MembersOrStockholdersInd
Election Of Board MembersYes (1)ElectionOfBoardMembersInd
Decisions Subject To ApprovaYes (1)DecisionsSubjectToApprovaInd
Minutes Of Governing BodyYes (1)MinutesOfGoverningBodyInd
Minutes Of CommitteesYes (1)MinutesOfCommitteesInd
Officer Mailing Address0OfficerMailingAddressInd
Local Chapters0LocalChaptersInd
Form990 Provided To Gvrn Body0Form990ProvidedToGvrnBodyInd
Conflict Of Interest PolicyYes (1)ConflictOfInterestPolicyInd
Annual Disclosure Covered PrsnYes (1)AnnualDisclosureCoveredPrsnInd
Regular Monitoring EnfrcYes (1)RegularMonitoringEnfrcInd
Whistleblower Policy0WhistleblowerPolicyInd
Document Retention Policy0DocumentRetentionPolicyInd
Compensation Process CEO0CompensationProcessCEOInd
Compensation Process OtherYes (1)CompensationProcessOtherInd
Investment In Joint Venture0InvestmentInJointVentureInd
States Where Copy Of Return Is FldCAStatesWhereCopyOfReturnIsFldCd
Upon RequestYes (X)UponRequestInd

Books In Care Of Detail BooksInCareOfDetail

Business Name BusinessName

FieldValueIRS element (for citing)
Business Name Line1DEBBIE BOTTENBusinessNameLine1Txt
FieldValueIRS element (for citing)
Phone3104238473PhoneNum

US Address USAddress

FieldValueIRS element (for citing)
Address Line115821 VENTURA BLVD STE 520AddressLine1Txt
CityENCINOCityNm
State AbbreviationCAStateAbbreviationCd
ZIP91436ZIPCd

Form990 Part VII Section A Form990PartVIISectionAGrp (6 entries)

TitleTitleTxtAverage Hours Per WeekAverageHoursPerWeekRtAverage Hours Per Week Rltd OrgAverageHoursPerWeekRltdOrgRtIndividual Trustee Or DirectorIndividualTrusteeOrDirectorIndOfficerOfficerIndReportable Comp From OrgReportableCompFromOrgAmtReportable Comp From Rltd OrgReportableCompFromRltdOrgAmtOther CompensationOtherCompensationAmt
JON KOBASHIGAWA MD
PRESIDENT2.000.00Yes (X)Yes (X)$0$0$0
MICHELE HAMILTON MD
CFO2.000.00Yes (X)Yes (X)$0$0$0
THOMAS D GORDON
DIRECTOR1.0040.00Yes (X)$0$549,717$76,122
EDUARDO MARBAN MD
DIRECTOR1.0060.00Yes (X)$0$2,335,876$202,989
JAIME MORIGUCHI MD
DIRECTOR2.000.00Yes (X)$0$0$0
CHRISTINE SUMBI
SECRETARY40.000.00Yes (X)$0$177,241$21,242
FieldValueIRS element (for citing)
Total Reportable Comp From Org$0TotalReportableCompFromOrgAmt
Tot Reportable Comp Rltd Org$3,062,834TotReportableCompRltdOrgAmt
Total Other Compensation$300,353TotalOtherCompensationAmt
Indiv Rcvd Greater Than100 K0IndivRcvdGreaterThan100KCnt
Former Ofcr Employees Listed0FormerOfcrEmployeesListedInd
Total Comp Greater Than150 KYes (1)TotalCompGreaterThan150KInd
Compensation From Other Srcs0CompensationFromOtherSrcsInd
Cntrct Rcvd Greater Than100 K0CntrctRcvdGreaterThan100KCnt
Related Organizations$1,466,549RelatedOrganizationsAmt
Total Contributions$1,466,549TotalContributionsAmt

Program Service Revenue ProgramServiceRevenueGrp (2 entries)

DescDescBusinessBusinessCdTotal Revenue ColumnTotalRevenueColumnAmtRelated Or Exempt Func IncomeRelatedOrExemptFuncIncomeAmt
EDUCATIONAL PROGRAMS611430$205,581$205,581
CULTURAL PROGRAMS611710$17,569$17,569
FieldValueIRS element (for citing)
Total Program Service Revenue$223,150TotalProgramServiceRevenueAmt

Total Revenue TotalRevenueGrp

FieldValueIRS element (for citing)
Total Revenue Column$1,689,699TotalRevenueColumnAmt
Related Or Exempt Func Income$223,150RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue$0UnrelatedBusinessRevenueAmt
Exclusion$0ExclusionAmt

Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp

FieldValueIRS element (for citing)
Total$179,595TotalAmt
Management And General$179,595ManagementAndGeneralAmt

Other Salaries And Wages OtherSalariesAndWagesGrp

FieldValueIRS element (for citing)
Total$1,012,008TotalAmt
Program Services$1,012,008ProgramServicesAmt

Pension Plan Contributions PensionPlanContributionsGrp

FieldValueIRS element (for citing)
Total$46,110TotalAmt
Program Services$46,110ProgramServicesAmt

Other Employee Benefits OtherEmployeeBenefitsGrp

FieldValueIRS element (for citing)
Total$59,802TotalAmt
Program Services$59,802ProgramServicesAmt

Payroll Taxes PayrollTaxesGrp

FieldValueIRS element (for citing)
Total$90,898TotalAmt
Program Services$90,898ProgramServicesAmt

Fees For Services Other FeesForServicesOtherGrp

FieldValueIRS element (for citing)
Total$36,196TotalAmt
Program Services$25,337ProgramServicesAmt
Management And General$10,859ManagementAndGeneralAmt

Office Expenses OfficeExpensesGrp

FieldValueIRS element (for citing)
Total$4,471TotalAmt
Program Services$4,024ProgramServicesAmt
Management And General$447ManagementAndGeneralAmt

Occupancy OccupancyGrp

FieldValueIRS element (for citing)
Total$54,462TotalAmt
Program Services$54,462ProgramServicesAmt

Travel TravelGrp

FieldValueIRS element (for citing)
Total$17,487TotalAmt
Program Services$17,487ProgramServicesAmt

Conferences Meetings ConferencesMeetingsGrp

FieldValueIRS element (for citing)
Total$183,119TotalAmt
Program Services$173,963ProgramServicesAmt
Management And General$9,156ManagementAndGeneralAmt

Depreciation Depletion DepreciationDepletionGrp

FieldValueIRS element (for citing)
Total$2,849TotalAmt
Program Services$2,849ProgramServicesAmt

Other Expenses OtherExpensesGrp (4 entries)

DescDescTotalTotalAmtProgram ServicesProgramServicesAmtManagement And GeneralManagementAndGeneralAmt
MEALS AND ENTERTAINMENT$28,383$9,651$18,732
DUES & SUBSCRIPTIONS$5,572$5,572
MOVING/STORAGE$2,160$2,160
CREDIT CARD FEES$1,239$1,239

All Other Expenses AllOtherExpensesGrp

FieldValueIRS element (for citing)
Total$2,608TotalAmt
Program Services$2,608ProgramServicesAmt

Total Functional Expenses TotalFunctionalExpensesGrp

FieldValueIRS element (for citing)
Total$1,726,959TotalAmt
Program Services$1,508,170ProgramServicesAmt
Management And General$218,789ManagementAndGeneralAmt
Fundraising$0FundraisingAmt

Cash Non Interest Bearing CashNonInterestBearingGrp

FieldValueIRS element (for citing)
BOY$48,209BOYAmt
EOY$23,258EOYAmt

Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp

FieldValueIRS element (for citing)
BOY$6,886BOYAmt
EOY$486EOYAmt
FieldValueIRS element (for citing)
Land Bldg Equip Cost Or Other Bss$107,678LandBldgEquipCostOrOtherBssAmt
Land Bldg Equip Accum Deprec$106,729LandBldgEquipAccumDeprecAmt

Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp

FieldValueIRS element (for citing)
BOY$3,798BOYAmt
EOY$949EOYAmt

Total Assets TotalAssetsGrp

FieldValueIRS element (for citing)
BOY$58,893BOYAmt
EOY$24,693EOYAmt

Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp

FieldValueIRS element (for citing)
BOY$124,806BOYAmt
EOY$127,865EOYAmt

Total Liabilities TotalLiabilitiesGrp

FieldValueIRS element (for citing)
BOY$124,806BOYAmt
EOY$127,865EOYAmt
FieldValueIRS element (for citing)
Organization Follows SFAS117Yes (X)OrganizationFollowsSFAS117Ind

Unrestricted Net Assets UnrestrictedNetAssetsGrp

FieldValueIRS element (for citing)
BOY-$65,913BOYAmt
EOY-$103,172EOYAmt

Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp

FieldValueIRS element (for citing)
BOY-$65,913BOYAmt
EOY-$103,172EOYAmt

Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp

FieldValueIRS element (for citing)
BOY$58,893BOYAmt
EOY$24,693EOYAmt
FieldValueIRS element (for citing)
Info In Schedule O Part XIYes (X)InfoInScheduleOPartXIInd
Reconcilation Revenue Expnss-$37,260ReconcilationRevenueExpnssAmt
Other Changes In Net Assets$1OtherChangesInNetAssetsAmt
Method Of Accounting AccrualYes (X)MethodOfAccountingAccrualInd
Accountant Compile Or Review0AccountantCompileOrReviewInd
FS Audited0FSAuditedInd
Federal Grant Audit Required0FederalGrantAuditRequiredInd

Schedule A IRS990ScheduleA

FieldValueIRS element (for citing)
Public Organization170Yes (X)PublicOrganization170Ind

Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$1,357,431CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$1,514,534CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$1,784,016CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$1,531,356CurrentTaxYearMinus1YearAmt
Current Tax Year$1,466,549CurrentTaxYearAmt
Total$7,653,886TotalAmt

Total Calendar Year170 TotalCalendarYear170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$1,357,431CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$1,514,534CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$1,784,016CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$1,531,356CurrentTaxYearMinus1YearAmt
Current Tax Year$1,466,549CurrentTaxYearAmt
Total$7,653,886TotalAmt
FieldValueIRS element (for citing)
Public Support Total170$7,653,886PublicSupportTotal170Amt

Gross Investment Income170 GrossInvestmentIncome170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$8,138CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$5,075CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$1,031CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$6CurrentTaxYearMinus1YearAmt
Current Tax Year$0CurrentTaxYearAmt
Total$14,250TotalAmt
FieldValueIRS element (for citing)
Total Support$7,668,136TotalSupportAmt
Gross Receipts Rltd Activities$778,007GrossReceiptsRltdActivitiesAmt
Public Support CY1700.99810PublicSupportCY170Pct
Public Support PY1700.99650PublicSupportPY170Pct
Thirty Thr Pct Suprt Tests CY170Yes (X)ThirtyThrPctSuprtTestsCY170Ind

Schedule B IRS990ScheduleB

Schedule D IRS990ScheduleD

Equipment EquipmentGrp

FieldValueIRS element (for citing)
Other Cost Or Other Basis$70,594OtherCostOrOtherBasisAmt
Depreciation$69,645DepreciationAmt
Book Value$949BookValueAmt

Other Land Buildings OtherLandBuildingsGrp

FieldValueIRS element (for citing)
Other Cost Or Other Basis$37,084OtherCostOrOtherBasisAmt
Depreciation$37,084DepreciationAmt
Book Value$0BookValueAmt
FieldValueIRS element (for citing)
Total Book Value Land Buildings$949TotalBookValueLandBuildingsAmt

Schedule J IRS990ScheduleJ

FieldValueIRS element (for citing)
Severance Payment0SeverancePaymentInd
Supplemental Nonqual Rtr PlanYes (1)SupplementalNonqualRtrPlanInd
Equity Based Comp Arrngm0EquityBasedCompArrngmInd
Comp Based On Revenue Of Flng Org0CompBasedOnRevenueOfFlngOrgInd
Comp Bsd On Rev Related Orgs0CompBsdOnRevRelatedOrgsInd
Comp Bsd Net Earns Flng Org0CompBsdNetEarnsFlngOrgInd
Comp Bsd Net Earns Rltd Orgs0CompBsdNetEarnsRltdOrgsInd
Any Non Fixed Payments0AnyNonFixedPaymentsInd
Initial Contract Exception0InitialContractExceptionInd

Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (3 entries)

TitleTitleTxtBase Compensation Filing OrgBaseCompensationFilingOrgAmtCompensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmtBonus Filing OrganizationBonusFilingOrganizationAmountBonus Related OrganizationsBonusRelatedOrganizationsAmtOther Compensation Filing OrgOtherCompensationFilingOrgAmtOther Compensation Rltd OrgsOtherCompensationRltdOrgsAmtDeferred Compensation Flng OrgDeferredCompensationFlngOrgAmtDeferred Comp Rltd OrgsDeferredCompRltdOrgsAmtNontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmtNontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmtTotal Compensation Filing OrgTotalCompensationFilingOrgAmtTotal Compensation Rltd OrgsTotalCompensationRltdOrgsAmtComp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmtComp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt
THOMAS D GORDON
DIRECTOR$0$278,758$0$0$0$270,959$0$64,079$0$12,043$0$625,839$0$0
EDUARDO MARBAN MD
DIRECTOR$0$1,411,760$0$368,108$0$556,008$0$168,900$0$34,089$0$2,538,865$0$0
CHRISTINE SUMBI
SECRETARY$0$158,201$0$18,701$0$339$0$12,571$0$8,671$0$198,483$0$0

Supplemental Information Detail SupplementalInformationDetail (2 entries)

Form And Line ReferenceFormAndLineReferenceDescExplanationExplanationTxt
PART I, LINE 3PLEASE SEE SCHEDULE O NARRATIVE FOR PART VI, SECTION B LINE 15B.
PART I, LINE 4BTHE PLAN IS A SUPPLEMENTAL RETIREMENT ALLOWANCE THAT IS PAYABLE DIRECTLY TO THE PARTICIPANTS EACH QUARTER. THE BENEFIT FORMULA FOR THIS PLAN HAS ANNUAL CONTRIBUTIONS THAT ARE EITHER A PERCENTAGE OF SALARY, OR ARE DESIGNED TO FUND A PERCENTAGE OF THE ESTIMATED FINAL 5-YEAR AVERAGE SALARY. THE FOLLOWING DIRECTORS RECEIVED PAYMENTS DURING THE YEAR ENDED DECEMBER 31, 2017. THOMAS D. GORDON 72,530 EDUARDO MARBAN, MD 317,082

Schedule O IRS990ScheduleO

Supplemental Information Detail SupplementalInformationDetail (11 entries)

Form And Line ReferenceFormAndLineReferenceDescExplanationExplanationTxt
FORM 990, PART III, LINE 4A(CONTINUED) CELL-FREE DNA AND ANTIBODY-MEDIATED REJECTION IN A COHORT OF SENSITIZED HEART TRANSPLANT PATIENTS; JON KOBASHIGAWA, MD; ENROLLMENT COMPLETE; CSMC/CAREDX, INC. THE DE-NOVO USE OF ECULIZUMAB ALONGSIDE CONVENTIONAL THERAPY IN PRESENSITIZED PATIENTS RECEIVING CARDIAC TRANSPLANTATION: AN OPEN-LABEL, INVESTIGATOR-INITIATED PILOT TRIAL; JIGNESH PATEL, MD, PHD; ENROLLMENT COMPLETE; ALEXION PHARMACEUTICALS ADVANCED HEART DISEASE BIOBANK; ROBIN SHAW, MD; ENROLLING; CSMC ADVANCED HEART DISEASE REGISTRY; JON KOBASHIGAWA, MD; ENROLLING; CSMC EXTERNAL FACTORS AND OUTCOMES FOR HEART TRANSPLANT RECIPIENTS: A SINGLE CENTER SURVEY STUDY; JON KOBASHIGAWA, MD; ENROLLING; CSMC IMMUNOLOGIC RISK STUDY; EVAN KRANSDORF, MD; STUDY START-UP; INTERNAL OBSERVATIONAL REVIEW OF CLINICAL OUTCOMES IN HEART FAILURE PATIENTS UNDERGOING BARIATRIC SURGERY; MICHELE HAMILTON, MD; ENROLLING; CSMC A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 3 STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL BPS-314D-MR ADDED-ON TO TREPROSTINIL, INHALED (TYVASO) IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION; ANTOINE HAGE, MD; CLOSED TO ENROLLMENT; LUNG BIOTECHNOLOGY, INC. A MULTICENTER, INTERNATIONAL, PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE (PF-06291826) 20 MG OR 80 MG IN COMPARISON TO PLACEBO IN SUBJECTS DIAGNOSED WITH TRANSTHYRETIN CARDIOMYOPATHY (TTR-CM); JIGNESH PATEL, MD, PHD; ENROLLMENT COMPLETE; PFIZER A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF INHALED TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION DUE TO PARENCHYMAL LUNG DISEASE; ANTOINE HAGE, MD; ENROLLING; UNITED THERAPEUTICS A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE 20MG OR 80MG IN SUBJECTS DIAGNOSED WITH TRANSTHYRETIN CARDIOMYOPATHY (TTR-CM); JIGNESH PATEL, MD, PHD; STUDY START-UP; PFIZER A PILOT RANDOMIZED STUDY TO ASSESS THE EFFECT AND SAFETY PROFILE OF THYMOGLOBULIN IN PRIMARY CARDIAC TRANSPLANT RECIPIENTS: A 12-MONTH, SINGLE CENTER, RANDOMIZED, OPEN-LABEL STUDY OF EFFICACY COMPARING IMMEDIATE TREATMENT WITH AND WITHOUT THYMOGLOBULIN 1.5 MG/KG/D FOR 5 CONSECUTIVE DAYS IN HEART TRANSPLANT RECIPIENTS; JON KOBASHIGAWA, MD; SCREENING; SANOFI A PROSPECTIVE, RANDOMIZED, CONTROLLED, UNBLINDED, MULTI-CENTER CLINICAL TRIAL TO EVALUATE THE HEARTWARE VENTRICULAR ASSIST DEVICE SYSTEM FOR DESTINATION THERAPY OF ADVANCED HEART FAILURE; JAIME MORIGUCHI, MD; ENROLLING; HEARTWARE, INC. A STUDY OF THE EFFICACY AND SAFETY OF BARDOXOLONE METHYL IN PATIENTS WITH CONNECTIVE TISSUE DISEASE-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION; ANTOINE HAGE, MD; ENROLLING; REATA PHARMACEUTICALS, INC. AN OPEN-LABEL EXTENSION STUDY OF INHALED TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION DUE TO PARENCHYMAL LUNG DISEASE; ANTOINE HAGE, MD; ENROLLING; UNITED THERAPEUTICS AN OPEN-LABEL EXTENSION STUDY OF UT-15C IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION - A LONG-TERM FOLLOW-UP TO PROTOCOL TDE-PH-310; ANTOINE HAGE, MD; ENROLLING; UNITED THERAPEUTICS CARDIOMEMS HF SYSTEM POST APPROVAL STUDY; LAWRENCE CZER, MD; ENROLLING; ST. JUDE MEDICAL DREAM-HF - A DOUBLE-BLIND, RANDOMIZED, SHAM-PROCEDURE-CONTROLLED, PARALLEL-GROUP EFFICACY AND SAFETY STUDY OF ALLOGENEIC MESENCHYMAL PRECURSOR CELLS (CEP-41750) IN PATIENTS WITH CHRONIC HEART FAILURE DUE TO LEFT VENTRICULAR SYSTOLIC DYSFUNCTION OF EITHER ISCHEMIC OR NONISCHEMIC ETIOLOGY; DAVID CHANG, MD; ENROLLING; MESOBLAST, INC. GALACTIC HF STUDY - A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF OMECAMTIV MECARBIL ON MORTALITY AND MORBIDITY IN SUBJECTS WITH CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION; DAVID CHANG, MD; ENROLLING; AMGEN OUTCOMES ALLOMAP REGISTRY (OAR) STUDY; JON KOBASHIGAWA, MD; ENROLLING; CAREDX, INC. PULMONARY HYPERTENSION POST-LEFT VENTRICULAR ASSIST DEVICE IMPLANTATION; JAIME MORIGUCHI, MD ENROLLING; ACTELION PHARMACEUTICALS RANGER - AN EXTENDED ACCESS PROGRAM TO ASSESS LONG-TERM SAFETY OF BARDOXOLONE METHYL IN PATIENTS WITH PULMONARY HYPERTENSION; ANTOINE HAGE, MD; ENROLLING; REATA PHARMACEUTICALS, INC. SERENADE - A MULTI-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MACITENTAN IN SUBJECTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION AND PULMONARY VASCULAR DISEASE; ANTOINE HAGE, MD; ENROLLING; ACTELION PHARMACEUTICALS SOUTHPAW - AN OPEN-LABEL EXTENSION STUDY OF ORAL TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION (PH) ASSOCIATED WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF) - A LONG-TERM FOLLOW-UP TO STUDY TDE-HF-301; ANTOINE HAGE, MD; ENROLLING; UNITED THERAPEUTICS STUDY TO EVALUATE THE EFFECT OF DAPAGLIFLOZIN ON THE INCIDENCE OF WORSENING HEART FAILURE OR CARDIOVASCULAR DEATH IN PATIENTS WITHCHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION; JIGNESH PATEL, MD, PHD; CLOSED TO ENROLLMENT; ASTRAZENECA US-BASED, OBSERVATIONAL, DRUG REGISTRY OF OPSUMIT (MACITENTAN) NEW USERS IN CLINICAL PRACTICE; ANTOINE HAGE, MD; ENROLLING; ACTELION PHARMACEUTICALS BIOMARKERS OF PRIMARY GRAFT DYSFUNCTION AFTER CARDIAC TRANSPLANTATION; JON KOBASHIGAWA, MD; ENROLLMENT COMPLETE; COLUMBIA UNIVERSITY CASH STUDY - CARDIAC SURGERY AFTER HEART TRANSPLANTATION - AN EXPLORATORY, RETROSPECTIVE, MULTICENTER STUDY; JON KOBASHIGAWA, MD; RETROSPECTIVE; MEDICAL UNIVERSITY OF VIENNA DIAGNOSTIC AND THERAPEUTIC APPLICATIONS OF MICROARRAYS IN HEART TRANSPLANTATION, A MULTICENTER STUDY; JON KOBASHIGAWA, MD; ENROLLING; UNIVERSITY OF ALBERTA ENTRESTOTM (LCZ696) IN ADVANCED HEART FAILURE (LIFE STUDY); EVAN KRANSDORF, MD; ENROLLING; DUKE UNIVERSITY INTERAGENCY REGISTRY FOR MECHANICALLY ASSISTED CIRCULATORY SUPPORT; DANNY RAMZY, MD, PHD; ENROLLING; UAB/NIH REGISTRY EVALUATION OF VITAL INFORMATION FOR VADS IN AMBULATORY LIFE; MICHELLE KITTLESON, MD, PHD; ENROLLMENT COMPLETE; UNIVERSITY OF MICHIGAN TRANSPLANT OF REDEEMED ORGANS BY JUDICIOUS ADMINISTRATION OF NEW DIRECT-ACTING ANTIVIRALS FOR HEPATITIS-C HEART RECIPIENTS (TROJAN-C); EVAN KRANSDORF, MD; STUDY START-UP; BAYLOR UNIVERSITY
FORM 990, PART IV, LINE 12THE ORGANIZATION WAS INCLUDED IN A CONSOLIDATED, INDEPENDENT AUDITED FINANCIAL STATEMENTS FOR THE FISCAL YEARS ENDED 6/30/17 AND 6/30/18 DUE TO THE FACT THAT THE TAX YEAR OF ITS TAX-EXEMPT PARENT ORGANIZATION, CEDARS-SINAI MEDICAL CENTER, ENDS ON 6/30. THERE ARE NO AUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 12/31/17.
FORM 990, PART VI, SECTION A, LINE 4THE BY-LAWS OF THE ORGANIZATION WERE RESTATED DURING THE TAX YEAR, AND THE AUTHORIZED NUMBER OF DIRECTORS WERE REVISED TO BE NOT LESS THAN FIVE NOR MORE THAN NINE.
FORM 990, PART VI, SECTION A, LINE 6CEDARS-SINAI MEDICAL CENTER IS THE SOLE CORPORATE MEMBER OF CALIFORNIA HEART CENTER FOUNDATION.
FORM 990, PART VI, SECTION A, LINE 7ACEDARS-SINAI MEDICAL CENTER AS THE SOLE CORPORATE MEMBER, CAN ELECT BOARD OF DIRECTORS TO CALIFORNIA HEART CENTER FOUNDATION.
FORM 990, PART VI, SECTION A, LINE 7BRESERVED RIGHTS OF CEDARS-SINAI MEDICAL CENTER, THE SOLE CORPORATE MEMBER OF THE ORGANIZATION. THE FOLLOWING ACTIONS MUST BE APPROVED OR ACTED UPON BY CEDARS-SINAI MEDICAL CENTER BEFORE BECOMING EFFECTIVE: (A) ANY SALE OR OTHER DISPOSITION OF ALL OR A SUBSTANTIAL PORTION OF THE ASSETS OF THE ORGANIZATION; (B) ANY MERGER OR AFFILIATION OF THE ORGANIZATION WITH ANY PERSON OR ENTITY OTHER THAN THE MEMBER; (C) ANY AMENDMENT TO THE ARTICLES OF INCORPORATION OR BYLAWS OF THE ORGANIZATION; (D) ANY ACT OR OMISSION WHICH CREATES ANY MATERIAL RISK TO THE MEMBER'S TAX EXEMPT STATUS, OR CREATES ANY MATERIAL RISK OF A VIOLATION OF ANY STATE OR FEDERAL LAWS; (E) DISSOLUTION OF THE ORGANIZATION OR THE FILING OF ANY BANKRUPTCY PETITION; (F) CREATION OF ANY NEW CORPORATION, PARTNERSHIP OR ASSOCIATION; (G) ACQUISITION OF OR THE INVESTMENT IN A NEW OPERATING BUSINESS; (H) ENTERING INTO ANY PARTNERSHIPS OR JOINT VENTURES; (I) ADOPTION OF OR CHANGES TO OPERATING OR CAPITAL BUDGETS; (J) ADOPTION OF THIS CORPORATION'S POLICIES AND PROCEDURES; (K) EXECUTION AND DELIVERY OF ANY NEW AFFILIATION AGREEMENTS AND OTHER RELATIONSHIPS WITH THE UCLA SCHOOL OF MEDICINE AND OTHER INSTITUTIONS OF MEDICAL LEARNING; (L) UNBUDGETED CAPITAL EXPENDITURES OVER $100,000; (M) LOANS, BORROWINGS OR GUARANTEES IN EXCESS OF $100,000, UNLESS APPROVED IN THE BUDGET; (N) ANY SECURITY INTERESTS OR MORTGAGES ON THE PROPERTY OF ORGANIZATION; (O) OPERATING OR CAPITAL LEASES WHERE THE TERM IS OVER FIVE YEARS OR THE TOTAL OBLIGATION UNDER THE LEASE EXCEEDS $100,000, UNLESS APPROVED IN THE BUDGET; (P) TERMINATION OR SELECTION OF THE AUDITORS OF THE ORGANIZATION; (Q) APPOINTMENT OR REMOVAL OF ANY MEMBER OF THE BOARD (OTHER THAN EX-OFFICIO DIRECTORS); (R) APPOINTMENT OF REMOVAL OF ANY OFFICERS; (S) EXECUTION AND DELIVERY OF ANY PROFESSIONAL SERVICE AGREEMENTS; (T) RELOCATION OF PRINCIPAL OFFICE; AND (U) FIXING THE NUMBER OF DIRECTORS OF THE ORGANIZATION.
FORM 990, PART VI, SECTION B, LINE 11BTHE ORGANIZATION'S FORM 990 UNDERGOES AN INTENSE AND HIGHLY COMPREHENSIVE REVIEW PROCESS. THE REVIEW INVOLVES VARIOUS MANAGEMENT PERSONNEL AND A BIG FOUR ACCOUNTING FIRM.
FORM 990, PART VI, SECTION B, LINE 12CCONFLICT OF INTEREST POLICY ANNUAL STATEMENTS: EACH DIRECTOR, OFFICER, MEMBER OF A COMMITTEE WITH BOARD-DELEGATED POWERS AND ANY OTHER INTERESTED PERSON AS DETERMINED BY THE BOARD OR COMMITTEE SHALL AT LEAST ANNUALLY SIGN A COPY OF THE "STATEMENT PERTAINING TO CONFLICT OF INTEREST." IF A DIRECTOR, OFFICER, OR COMMITTEE MEMBER, OR DESIGNATED INTERESTED PERSON BECOMES AWARE THAT A POTENTIAL OR APPARENT CONFLICT MAY EXIST WHICH IS NOT DISCLOSED ON SUCH A STATEMENT, IT SHALL BE THE RESPONSIBILITY OF THE INTERESTED PERSON TO DISCLOSE THE POTENTIAL CONFLICT TO THE PRESIDENT AND TO THE BOARD OR APPROPRIATE COMMITTEE AND AS SET FORTH ABOVE, PRIOR TO ANY BOARD OR COMMITTEE DISCUSSIONS OR ACTION WITH RESPECT TO THE RELEVANT TRANSACTION OR ARRANGEMENT, AND, IF RELEVANT, TO LEAVE THE MEETING DURING THE DISCUSSION AND VOTE ON THE TRANSACTION OR ARRANGEMENT. DETERMINING WHETHER A CONFLICT OF INTEREST EXISTS: IF CONSIDERATION OF THE TRANSACTION OR ARRANGEMENT AT ISSUE IS A MATTER WITHIN THE SCOPE OF AUTHORITY OF THE BOARD OF DIRECTORS OR A COMMITTEE, AFTER DISCLOSURE OF THE FINANCIAL INTEREST AND AFTER ANY DISCUSSION WITH THE INTERESTED PERSON, THE RELEVANT CALIFORNIA HEART CENTER FOUNDATION ("CHCF") OFFICER OR ADMINISTRATOR SHALL DETERMINE WHETHER A CONFLICT OF INTEREST EXISTS. IF IT IS DETERMINED THAT A CONFLICT OF INTEREST EXISTS AND, NOTWITHSTANDING THE CONFLICT, THE CHCF OFFICER OR ADMINISTRATOR DETERMINES THAT IT CONTINUES TO BE IN THE BEST INTERESTS OF CHCF TO PROCEED WITH THE TRANSACTION OR ARRANGEMENT AT ISSUE, THE CHCF OFFICER OR ADMINISTRATOR SHALL REFER THE TRANSACTION OR ARRANGEMENT TO THE BOARD OR THE APPROPRIATE BOARD-DESIGNATED COMMITTEE FOR EVALUATION. ALTERNATIVELY IF CONSIDERATION OF THE TRANSACTION OR ARRANGEMENT AT ISSUE IS A MATTER WITHIN THE SCOPE OF THE AUTHORITY OF THE BOARD OF DIRECTORS OR A COMMITTEE, THE INTERESTED PERSON SHALL LEAVE THE BOARD OR COMMITTEE MEETING WHILE THE DETERMINATION OF THE EXISTENCE OF A CONFLICT OF INTEREST IS DISCUSSED AND VOTED UPON. THE REMAINING BOARD OR COMMITTEE MEMBERS SHALL DECIDE, BY MAJORITY VOTE, IF A CONFLICT OF INTEREST EXISTS. PROCEDURES FOR ADDRESSING THE CONFLICT OF INTEREST: A. AN INTERESTED PERSON MAY MAKE A PRESENTATION TO THE BOARD OR COMMITTEE REGARDING THE TRANSACTION OR ARRANGEMENT. AFTER SUCH PRESENTATION THE INTERESTED PERSON MUST LEAVE THE MEETING DURING THE DISCUSSION OF, AND THE VOTE ON THE TRANSACTION OR ARRANGEMENT. B. THE CHAIR OF THE BOARD OR COMMITTEE SHALL, IF DEEMED APPROPRIATE BY THE BOARD OR COMMITTEE, APPOINT A DISINTERESTED PERSON OR COMMITTEE TO INVESTIGATE ALTERNATIVES TO THE PROPOSED TRANSACTION OR ARRANGEMENT. C. AFTER EXERCISING DUE DILIGENCE, THE BOARD OR COMMITTEE SHALL DETERMINE WHETHER CHCF CAN OBTAIN A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT WITH REASONABLE EFFORTS FROM A PERSON OR ENTITY THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. D. IF A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT IS NOT REASONABLY ATTAINABLE UNDER CIRCUMSTANCES THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST, THE BOARD OR COMMITTEE SHALL DETERMINE BY A MAJORITY VOTE OF THE DISINTERESTED DIRECTORS WHETHER THE TRANSACTION OR ARRANGEMENT IS IN CHCF' BEST INTEREST AND FOR ITS OWN BENEFIT AND WHETHER THE TRANSACTION IS FAIR AND REASONABLE TO CHCF AND SHALL MAKE ITS DECISION AS TO WHETHER TO ENTER INTO THE TRANSACTION OR ARRANGEMENT IN CONFORMITY WITH SUCH DETERMINATION. VIOLATIONS OF THE CONFLICTS POLICY: A. IF THE BOARD OR COMMITTEE HAS REASONABLE CAUSE TO BELIEVE THAT A MEMBER OF THE BOARD OR COMMITTEE OR AN OFFICER OR OTHER INTERESTED PERSON HAS FAILED TO DISCLOSE AN ACTUAL OR POSSIBLE CONFLICT OF INTEREST, IT SHALL INFORM THE MEMBER OR OFFICER OR INTERESTED PERSON OF THE BASIS FOR SUCH BELIEF AND AFFORD SUCH PERSON AN OPPORTUNITY TO EXPLAIN THE ALLEGED FAILURE TO DISCLOSE. B. IF, AFTER HEARING THE RESPONSE OF SUCH PERSON AND MAKING SUCH FURTHER INVESTIGATION AS MAY BE WARRANTED IN THE CIRCUMSTANCES, THE BOARD OR COMMITTEE DETERMINES THAT SUCH PERSON HAS IN FACT FAILED TO DISCLOSE AN ACTUAL OR POSSIBLE CONFLICT OF INTEREST, IT SHALL TAKE APPROPRIATE DISCIPLINARY AND CORRECTIVE ACTION.
FORM 990, PART VI, SECTION B, LINE 15BTHE EXECUTIVE PERSONNEL COMMITTEE (THE COMMITTEE) OF THE TAX-EXEMPT PARENT OF THE ORGANIZATION, CEDARS-SINAI MEDICAL CENTER, IS A STANDING COMMITTEE OF THE BOARD OF DIRECTORS. THE COMMITTEE ADDRESSES COMPENSATION AND BENEFITS REGARDING THE ORGANIZATION'S CHIEF FINANCIAL OFFICER AND BOARD MEMBERS WHO ARE ALSO EXECUTIVE EMPLOYEES AND CONTRACTUALLY ENGAGED FACULTY OF THE MEDICAL CENTER, AND IS AUTHORIZED BY THE BOARD OF DIRECTORS TO ACT ON BEHALF OF THE BOARD WITH RESPECT TO SUCH ISSUES, AND OTHER GOVERNANCE ISSUES AS REQUESTED BY THE BOARD OF DIRECTORS, THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS, THE CHAIR OF THE BOARD OF DIRECTORS, OR THE CEO, ALL SUBJECT TO THE COMMITTEE'S ONGOING REPORTING OBLIGATION TO THE BOARD OF DIRECTORS OR THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS. SPECIFICALLY, THE COMMITTEE EVALUATES THE PERFORMANCE AND APPROVES THE COMPENSATION AND BENEFITS FOR THE ORGANIZATION'S CHIEF FINANCIAL OFFICER AND BOARD MEMBERS WHO ARE ALSO EXECUTIVE EMPLOYEES AND CONTRACTUALLY ENGAGED FACULTY OF THE MEDICAL CENTER. THE MEMBERS OF THE COMMITTEE ARE APPOINTED ANNUALLY BY THE CHAIR OF THE MEDICAL CENTER'S BOARD OF DIRECTORS. APPOINTMENTS ARE FOR A ONE YEAR TERM. EACH YEAR, THE COMMITTEE FOLLOWS A PROCESS THAT ENSURES THAT THE COMPENSATION AND BENEFITS IS REASONABLE AND IN COMPLIANCE WITH APPLICABLE LAWS AND REGULATIONS. THE MEDICAL CENTER'S SVP OF HR PROVIDES STAFF SUPPORT TO THE COMMITTEE. THE COMMITTEE MAY INCLUDE MEMBERS OF THE MEDICAL CENTER'S MANAGEMENT TEAM OR ANY OTHER PERSON WHOSE PRESENCE THE COMMITTEE BELIEVES TO BE DESIRABLE OR APPROPRIATE. THE COMMITTEE MAY ENGAGE AN INDEPENDENT COMPENSATION AND BENEFITS CONSULTANT AND ANY OTHER ADVISORS THEY DEEM NECESSARY. THE COMMITTEE MAY ALSO ENGAGE INDEPENDENT COUNSEL. THE MEDICAL CENTER WILL PROVIDE FOR APPROPRIATE FUNDING FOR PAYMENT OF COSTS TO ANY SUCH PERSONS RETAINED BY THE COMMITTEE. ANNUALLY, AT THE COMMITTEE'S DIRECTION, THE INDEPENDENT COMPENSATION CONSULTANT SHALL PREPARE SUCH REPORTS AS THE COMMITTEE REASONABLY DEEMS NECESSARY. AT A MINIMUM, SUCH REPORTS WILL INCLUDE MARKET SURVEY DATA FROM A PEER GROUP DESIGNATED BY THE COMMITTEE, WHICH SHALL BE CONSIDERED BY THE COMMITTEE PRIOR TO MAKING DECISIONS. THE COMMITTEE MEETS AS FREQUENTLY AS THE COMMITTEE DEEMS NECESSARY AND WILL MAINTAIN WRITTEN MINUTES OF ITS MEETING. THE COMPENSATION AND BENEFITS OF THE PRESIDENT AND VICE-PRESIDENT ARE DETERMINED BY THE CHIEF FINANCIAL OFFICER OF THE ORGANIZATION WITH ASSISTANCE FROM HR WHICH PROVIDES AN INDEPENDENT REVIEW OF COMPARABLES.
FORM 990, PART VI, SECTION C, LINE 19THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, ITS CONFLICT OF INTEREST POLICY AND ITS TAX-EXEMPT PARENT'S AUDITED FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON WRITTEN REQUEST.
FORM 990, PART XI, LINE 9:ROUNDING 1.

Schedule R IRS990ScheduleR

Id Related Tax Exempt Org IdRelatedTaxExemptOrgGrp (6 entries)

Address Line1USAddress/AddressLine1TxtCityUSAddress/CityNmState AbbreviationUSAddress/StateAbbreviationCdZIPUSAddress/ZIPCdEINEINPrimary ActivitiesPrimaryActivitiesTxtLegal Domicile StateLegalDomicileStateCdExempt Code SectionExemptCodeSectionTxtPublic Charity StatusPublicCharityStatusTxtBusiness Name Line1DirectControllingEntityName/BusinessNameLine1TxtControlled OrganizationControlledOrganizationIndDirect Controlling NADirectControllingNACd
CEDARS-SINAI MEDICAL CENTER
8700 BEVERLY BOULEVARDLOS ANGELESCA90048951644600HEALTHCARECA501(C)(3)LINE 3CEDARS-SINAI HEALTH SYSTEM0
CEDARS-SINAI MEDICAL CARE FOUNDATION
200 N ROBERTSON BOULEVARD 101BEVERLY HILLSCA90211954457756PROVISION OF MEDICAL CARE, TEACHING AND RESEARCHCA501(C)(3)LINE 12A, ICEDARS-SINAI MEDICAL CENTERYes (1)
KERLAN-JOBE ORTHOPAEDIC FOUNDATION
6801 PARK TERRACELOS ANGELESCA90045954707606EDUCATION AND RESEARCH RELATED TO ORTHOPAEDIC MEDICINECA501(C)(3)LINE 7CEDARS-SINAI MEDICAL CARE FOUNDATIONYes (1)
SANTA MONICA ORTHOPAEDIC & SPORTS MED RESEARCH FDN
2020 SANTA MONICA BLVD 4TH FLRSANTA MONICACA90404954789926EDUCATION AND RESEARCH RELATED TO ORTHOPAEDIC AND NEUROLOGIC CONDITIONSCA501(C)(3)PFCEDARS-SINAI MEDICAL CARE FOUNDATIONYes (1)
CFHS HOLDINGS INC
4650 LINCOLN BLVDMARINA DEL REYCA90292201645949HEALTHCARECA501(C)(3)LINE 3CEDARS-SINAI MEDICAL CENTERYes (1)
CEDARS-SINAI HEALTH SYSTEM
8700 BEVERLY BOULEVARDLOS ANGELESCA90048300990905SUPPORT SPECIFIED NONPROFIT HEALTHCARE ORGANIZATIONSCA501(C)(3)LINE 12C, III-FI0N/A

Id Related Org Txbl Partnership IdRelatedOrgTxblPartnershipGrp (8 entries)

Address Line1USAddress/AddressLine1TxtCityUSAddress/CityNmState AbbreviationUSAddress/StateAbbreviationCdZIPUSAddress/ZIPCdEINEINPrimary ActivitiesPrimaryActivitiesTxtLegal Domicile StateLegalDomicileStateCdDirect Controlling NADirectControllingNACd
ENDOSCOPY CENTER OF SANTA MONICA LLC
12400 WILSHIRE BLVD STE 100LOS ANGELESCA90025113652210ENDOSCOPIES AND RELATED PROCEDURESCAN/A
ISS ASC HOLDINGS LLC
27271 LAS RAMBLAS STE 350MISSION VIEJOCA92691471890805INVESTMENT IN HEALTHCARE SERVICESCAN/A
DEL REY SURGERY INVESTORS LLC
11150 SANTA MONICA BLVD STE 700LOS ANGELESCA90025364756208INVESTMENT IN AMBULATORY SURGERY CENTERDEN/A
DEL REY SURGERY CENTER LLC
27271 LAS RAMBLAS STE 350MISSION VIEJOCA92691462305372OPERATOR OF AMBULATORY SURGERY CENTERCAN/A
CEDARS-SINAI BH ASC LLC
200 N ROBERTSON BLVD 101BEVERLY HILLSCA90211812266744HOLDING COMPANYCAN/A
CS-BH ASC HOLDINGS LLC
200 N ROBERTSON BLVD 101BEVERLY HILLSCA90211812246488HOLDING COMPANYCAN/A
INTERNATIONAL SPINE & ORTHOPEDIC INSTITUTE LLC
8500 W 110TH STOVERLAND PARKKS66210263738893SPINE AND ORTHOPEDIC INSTITUTEDEN/A
SANTA MONICA IMAGING GROUP LLC
200 N ROBERTSON BLVD 101BEVERLY HILLSCA90211820760657IMAGING CENTERCAN/A

Id Related Org Txbl Corp Tr IdRelatedOrgTxblCorpTrGrp (3 entries)

Address Line1USAddress/AddressLine1TxtCityUSAddress/CityNmState AbbreviationUSAddress/StateAbbreviationCdZIPUSAddress/ZIPCdEINEINPrimary ActivitiesPrimaryActivitiesTxtLegal Domicile StateLegalDomicileStateCdDirect Controlling NADirectControllingNACdEntity TypeEntityTypeTxtControlled OrganizationControlledOrganizationInd
OPTIMATRIX HEALTH SOLUTIONS INC
6500 WILSHIRE BLVD 9TH FLRLOS ANGELESCA90048954522779INFORMATION SYSTEMSCAN/ACYes (1)
CENTINELA FREEMAN HOLDINGS INC
4650 LINCOLN BLVDMARINA DEL REYCA90292593811890MEDICAL OFFICE BUILDING AND GROUND LEASE LESSORCAN/ACYes (1)
OTOHARMONICS CORPORATION
411 SW 6TH AVEPORTLANDOR97204461119421HEALTHCARE PRODUCT DEVELOPMENTDEN/ACYes (1)
FieldValueIRS element (for citing)
Receipt Of Int Annts Rnts Rylts0ReceiptOfIntAnntsRntsRyltsInd
Gift Grnt Or Cap Contri To Oth Org0GiftGrntOrCapContriToOthOrgInd
Gift Grnt Cap Contri From Oth OrgYes (1)GiftGrntCapContriFromOthOrgInd
Loans Or Guarantees To Other Org0LoansOrGuaranteesToOtherOrgInd
Loans Or Guarantees From Oth Org0LoansOrGuaranteesFromOthOrgInd
Div Related Organization0DivRelatedOrganizationInd
Asset Sale To Other Org0AssetSaleToOtherOrgInd
Asset Purchase From Other Org0AssetPurchaseFromOtherOrgInd
Asset Exchange0AssetExchangeInd
Rental Of Facilities To Oth Org0RentalOfFacilitiesToOthOrgInd
Rental Of Fclts From Oth Org0RentalOfFcltsFromOthOrgInd
Perform Of Services For Oth Org0PerformOfServicesForOthOrgInd
Perform Of Services By Other Org0PerformOfServicesByOtherOrgInd
Sharing Of FacilitiesYes (1)SharingOfFacilitiesInd
Paid Employees SharingYes (1)PaidEmployeesSharingInd
Reimbursement Paid To Other OrgYes (1)ReimbursementPaidToOtherOrgInd
Reimbursement Paid By Other Org0ReimbursementPaidByOtherOrgInd
Transfer To Other Org0TransferToOtherOrgInd
Transfer From Other Org0TransferFromOtherOrgInd

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.